ARTICLE | Clinical News
Memantine regulatory update
February 3, 2003 8:00 AM UTC
The FDA accepted for filing FRX's NDA for memantine to treat moderate to severe Alzheimer's disease (AD). FRX resubmitted the NDA in December 2002, after originally withdrawing it in September (see Bi...